Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
33.95 GBX | +1.65% | -1.68% | -46.33% |
Mar. 27 | Jefferies Downgrades Life Science REIT to Hold from Buy, Cuts PT | MT |
Mar. 27 | Sorted renews M&S deal; Tribe completes drill build | AN |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 354.4 | 253 | 221.2 | 116.9 | - | - |
Enterprise Value (EV) 1 | 354.4 | 207.4 | 314.8 | 247.3 | 263.5 | 273 |
P/E ratio | 46 x | -9.15 x | -10.2 x | 10.8 x | 8.15 x | 5.66 x |
Yield | - | 5.53% | 6.33% | 6.24% | 7.37% | 8.68% |
Capitalization / Revenue | - | 19.5 x | 16 x | 6.24 x | 5.23 x | 4.7 x |
EV / Revenue | - | 16 x | 22.8 x | 13.2 x | 11.8 x | 11 x |
EV / EBITDA | - | 93.6 x | 36.7 x | 19.6 x | 16 x | 14.7 x |
EV / FCF | - | - | -19.2 x | -124 x | 264 x | 273 x |
FCF Yield | - | - | -5.22% | -0.81% | 0.38% | 0.37% |
Price to Book | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 350,000 | 350,000 | 350,000 | 350,000 | - | - |
Reference price 2 | 1.012 | 0.7230 | 0.6320 | 0.3340 | 0.3340 | 0.3340 |
Announcement Date | 5/23/22 | 3/27/23 | 3/26/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net sales 1 | - | 12.97 | 13.8 | 18.74 | 22.33 | 24.9 |
EBITDA 1 | - | 2.217 | 8.576 | 12.6 | 16.5 | 18.6 |
EBIT | - | - | - | - | - | - |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -27.47 | -21.85 | 10.8 | 14.4 | 20.5 |
Net income 1 | 7.741 | -27.61 | -21.71 | 10.8 | 14.4 | 20.5 |
Net margin | - | -212.92% | -157.29% | 57.64% | 64.48% | 82.34% |
EPS 2 | 0.0220 | -0.0790 | -0.0620 | 0.0310 | 0.0410 | 0.0590 |
Free Cash Flow 1 | - | - | -16.42 | -2 | 1 | 1 |
FCF margin | - | - | -118.98% | -10.67% | 4.48% | 4.02% |
FCF Conversion (EBITDA) | - | - | - | - | 6.06% | 5.38% |
FCF Conversion (Net income) | - | - | - | - | 6.94% | 4.88% |
Dividend per Share 2 | - | 0.0400 | 0.0400 | 0.0208 | 0.0246 | 0.0290 |
Announcement Date | 5/23/22 | 3/27/23 | 3/26/24 | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | 93.6 | 130 | 147 | 156 |
Net Cash position 1 | - | 45.6 | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | 10.91 x | 10.35 x | 8.885 x | 8.392 x |
Free Cash Flow 1 | - | - | -16.4 | -2 | 1 | 1 |
ROE (net income / shareholders' equity) | - | - | 2.22% | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - |
Capex 1 | - | - | 24 | 33 | 22 | 10 |
Capex / Sales | - | - | 174.16% | 176.13% | 98.51% | 40.17% |
Announcement Date | 5/23/22 | 3/27/23 | 3/26/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-46.33% | 149M | |
+3.79% | 27.36B | |
+6.92% | 24.64B | |
+1.76% | 21.31B | |
+4.91% | 16.68B | |
+0.33% | 15.62B | |
-11.70% | 14.71B | |
+0.25% | 13.2B | |
+1.38% | 12.72B | |
-10.66% | 11.71B |
- Stock Market
- Equities
- LABS Stock
- Financials Life Science REIT plc